Muscle-derived autologous stem cell therapy - U.S. Stem Cell

Drug Profile

Muscle-derived autologous stem cell therapy - U.S. Stem Cell

Alternative Names: Implanted autologous skeletal myoblasts - U.S. Stem Cell; Myoblast-derived autologous stem cell therapy - U.S. Stem Cell; MyoCell; MyoCell II; MyoCell SDF-1; Second-generation MyoCell SDF-1 myogenic cell composition - U.S. Stem Cell

Latest Information Update: 28 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bioheart
  • Developer AnC Bio; Bioheart; Magnum Cell Therapies; Revita Life Sciences; U.S. Stem Cell
  • Class Cardiovascular therapies; Cell therapies; Heart failure therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Heart failure
  • No development reported Myocardial infarction

Most Recent Events

  • 28 Feb 2017 Bioheart plans a phase I trial for Heart failure, Myocardial infarction and Coronary artery disease in USA (NCT00050765)
  • 04 Dec 2015 Bioheart is now called US Stemcell
  • 19 Jun 2015 Phase-II/III development of MyoCell® for Heart failure is ongoing in USA and Europe
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top